STI571 reduces TRAIL-induced apoptosis in colon cancer cells: C-Abl activation by the death receptor leads to stress kinase-dependent cell death

Journal of Biomedical Science

Volumn 19, Issue 1, 2012, Pages

  Huang, Duen Yi ^a   Chao, Yee ^b   Tai, Ming Hui ^a   Yu, Yang Hao ^c,d   Lin, Wan Wan ^a,e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Antitumor; Apoptosis; STI571; Stress kinases; TRAIL

Indexed keywords

ABELSON KINASE; CASPASE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P73; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; DNA BINDING PROTEIN; NUCLEAR PROTEIN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TNFSF10 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL DEATH; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; WESTERN BLOTTING; CELL STRAIN K 562; CELL SURVIVAL; COLON TUMOR; DRUG EFFECT; GENETICS; METABOLISM;

APOPTOSIS; CELL SURVIVAL; COLONIC NEOPLASMS; DNA-BINDING PROTEINS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; K562 CELLS; NUCLEAR PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR SUPPRESSOR PROTEINS;

EID: 84859071134     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-19-35     Document Type: Article

References (57)

1. Apoptosis control by death and decoy receptors. Ashkenazi A, Dixit VM, Curr Opin Cell Biol 1999 11 255 260 10.1016/S0955-0674(99)80034-9 10209153 (Pubitemid 29164042)
2. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Ozoren N, El-Deiry WS, Neoplasia 2002 4 551 557 10.1038/sj.neo.7900270 12407450 (Pubitemid 35417080)
3. Tumor therapeutics by design: targeting and activation of death receptors. Wajant H, Gerspach J, Pfizenmaier K, Cytokine Growth Factor Rev 2005 16 55 76 10.1016/j.cytogfr.2004.12.001 15733832 (Pubitemid 40279117)
4. The involvement of reactive oxygen species (ROS) and p38 mitogen- activated protein (MAP) kinase in TRAIL/Apo2L-induced apoptosis. Lee MW, Park SC, Yang YG, Yim SO, Chae HS, Bach JH, Lee HJ, Kim KY, Lee WB, Kim SS, FEBS Lett 2002 512 313 318 10.1016/S0014-5793(02)02225-1 11852102 (Pubitemid 34164501)
5. TRAIL signalling: decisions between life and death. Falschlehner C, Emmerich CH, Gerlach B, Walczak H, Int J Biochem Cell Biol 2007 39 1462 1475 10.1016/j.biocel.2007.02.007 17403612 (Pubitemid 47031030)
6. Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors. Singer CF, Hudelist G, Lamm W, Mueller R, Czerwenka K, Kubista E, Endocr Relat Cancer 2004 11 861 869 10.1677/erc.1.00801 15613459 (Pubitemid 40065558)
7. The Abl family kinases: mechanisms of regulation and signaling. Pendergast AM, Adv Cancer Res 2002 85 51 100 12374288
8. Tumor necrosis factor alpha-induced apoptosis requires p73 and c-ABL activation downstream of RB degradation. Chau BN, Chen TT, Wan YY, DeGregori J, Wang JY, Mol Cell Biol 2004 24 4438 4447 10.1128/MCB.24.10.4438-4447.2004 15121862 (Pubitemid 41071013)
9. Regulation of cell death by the Abl tyrosine kinase. Wang JY, Oncogene 2000 19 5643 5650 10.1038/sj.onc.1203878 11114745
10. Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase. Yuan ZM, Huang Y, Ishiko T, Kharbanda S, Weichselbaum R, Kufe D, Proc Natl Acad Sci USA 1997 94 1437 1440 10.1073/pnas.94.4.1437 9037071 (Pubitemid 27087869)
11. Cycling, stressed-out and nervous: cellular functions of c-Abl. Van Etten RA, Trends Cell Biol 1999 9 179 186 10.1016/S0962-8924(99)01549-4 10322452 (Pubitemid 29192985)
12. Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells. Dan S, Naito M, Seimiya H, Kizaki A, Mashima T, Tsuruo T, Oncogene 1999 18 1277 1283 10.1038/sj.onc.1202423 10022809 (Pubitemid 29094879)
13. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG Jr, Levrero M, Wang JY, Nature 1999 399 806 809 10.1038/21690 10391249 (Pubitemid 29293179)
14. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Lewis JM, Baskaran R, Taagepera S, Schwartz MA, Wang JY, Proc Natl Acad Sci USA 1996 93 15174 15179 10.1073/pnas.93.26.15174 8986783 (Pubitemid 27009572)
15. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Srinivasan D, Sims JT, Plattner R, Oncogene 2008 27 1095 1105 10.1038/sj.onc.1210714 17700528 (Pubitemid 351253178)
16. Inactivation of NF-kappaB-dependent cell survival, a novel mechanism for the proapoptotic function of c-Abl. Kawai H, Nie L, Yuan ZM, Mol Cell Biol 2002 22 6079 6088 10.1128/MCB.22.17.6079-6088.2002 12167702 (Pubitemid 34857828)
17. p73 induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, Corazzari M, Knight RA, Green DR, Thompson C, Vousden KH, J Biol Chem 2004 279 8076 8083 14634023 (Pubitemid 38294697)
18. p73 induces apoptosis by different mechanisms. Ramadan S, Terrinoni A, Catani MV, Sayan AE, Knight RA, Mueller M, Krammer PH, Melino G, Candi E, Biochem Biophys Res Commun 2005 331 713 717 10.1016/j.bbrc.2005.03.156 15865927 (Pubitemid 40615502)
19. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ, Blood 2000 96 925 932 10910906 (Pubitemid 30618049)
20. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H, N Engl J Med 2002 347 472 480 10.1056/NEJMoa020461 12181401 (Pubitemid 34879334)
21. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. Goldman JM, Melo JV, N Engl J Med 2001 344 1084 1086 10.1056/NEJM200104053441409 11287980 (Pubitemid 32267980)
22. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD, N Engl J Med 2001 344 1052 1056 10.1056/NEJM200104053441404 11287975 (Pubitemid 32267975)
23. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2 L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Nimmanapalli R, Porosnicu M, Nguyen D, Worthington E, O'Bryan E, Perkins C, Bhalla K, Clin Cancer Res 2001 7 350 357 11234890 (Pubitemid 32183039)
24. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation. Hama A, Richon C, Meslin F, Faure F, Kauffmann A, Lecluse Y, Jalil A, Larue L, Avril MF, Chouaib S, Mehrpour M, Oncogene 2006 25 7618 7634 10.1038/sj.onc.1209738 16983347 (Pubitemid 44924475)
25. Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand. Kikuchi S, Nagai T, Kunitama M, Kirito K, Ozawa K, Komatsu N, Cancer Sci 2007 98 1949 1958 10.1111/j.1349-7006.2007.00623.x 17900262 (Pubitemid 350002202)
26. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells. Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH, Exp Cell Res 2009 315 1809 1818 10.1016/j.yexcr.2009.02.024 19268463
27. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Uno K, Inukai T, Kayagaki N, Goi K, Sato H, Nemoto A, Takahashi K, Kagami K, Yamaguchi N, Yagita H, Okumura K, Koyama-Okazaki T, Suzuki T, Sugita K, Nakazawa S, Blood 2003 101 3658 3667 10.1182/blood-2002-06-1770 12506034 (Pubitemid 36857956)
28. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, Louvet C, Kornprobst M, André T, Mareel M, Mester J, Gespach C, Cancer Res 2002 62 4879 4883 12208734 (Pubitemid 34984407)
29. 5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNF-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling. Su RY, Chao Y, Chen TY, Huang DY, Lin WW, Mol Cancer Ther 2007 6 1562 1571 10.1158/1535-7163.MCT-06-0800 17513605 (Pubitemid 46954023)
30. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. Brasher BB, Van Etten RA, J Biol Chem 2000 275 35631 35637 10.1074/jbc.M005401200 10964922
31. Caspase-dependent cleavage of c-Abl contributes to apoptosis. Barila D, Rufini A, Condo I, Ventura N, Dorey K, Superti-Furga G, Testi R, Mol Cell Biol 2003 23 2790 2799 10.1128/MCB.23.8.2790-2799.2003 12665579 (Pubitemid 36403078)
32. Requirement of caspase-mediated cleavage of c-Abl during stress-induced apoptosis. Machuy N, Rajalingam K, Rudel T, Cell Death Differ 2004 11 290 300 10.1038/sj.cdd.4401336 14657961 (Pubitemid 38313138)
33. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Podar K, Raab MS, Tonon G, Sattler M, Baril D, Zhang J, Tai YT, Yasui H, Raje N, DePinho RA, Hideshima T, Chauhan D, Anderson KC, Cancer Res 2007 67 1680 1688 10.1158/0008-5472.CAN-06-1863 17308109 (Pubitemid 46383394)
34. Abl functions as a negative regulator of Met-induced cell motility via phosphorylation of the adapter protein CrkII. Cipres A, Abassi YA, Vuori K, Cell Signal 2007 19 1662 1670 10.1016/j.cellsig.2007.02.011 17399949 (Pubitemid 46935423)
35. Cytoplasmic c-Abl provides a molecular 'Rheostat' controlling carcinoma cell survival and invasion. Kain KH, Gooch S, Klemke RL, Oncogene 2003 22 6071 6080 10.1038/sj.onc.1206930 12955086 (Pubitemid 37175885)
36. Expression of immediate early gene pip92 during anisomycin-induced cell death is mediated by the JNK- and p38-dependent activation of Elk1. Chung KC, Kim SM, Rhang S, Lau LF, Gomes I, Ahn YS, Eur J Biochem 2000 267 4676 4684 10.1046/j.1432-1327.2000.01517.x 10903500 (Pubitemid 30619457)
37. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, Lu H, Kharbanda S, Weichselbaum R, Kufe D, Nature 1999 399 814 817 10.1038/21704 10391251 (Pubitemid 29293181)
38. Liposomal imatinib-mitoxantrone combination: formulation development and therapeutic evaluation in an animal model of prostate cancer. Pinto AC, Moreira JN, Simes S, Prostate 2011 71 81 90 10.1002/pros.21224 20607721
39. TRAIL-mediated signaling in prostate, bladder and renal cancer. Voelkel-Johnson C, Nat Rev Urol 2011 8 417 427 10.1038/nrurol.2011.81 21670755
40. Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. Stahtea XN, Roussidis AE, Kanakis I, Tzanakakis GN, Chalkiadakis G, Mavroudis D, Kletsas D, Karamanos NK, Int J Cancer 2007 121 2808 2814 10.1002/ijc.23029 17721919 (Pubitemid 350136431)
41. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL. El Fajoui Z, Toscano F, Jacquemin G, Abello J, Scoazec JY, Micheau O, Saurin JC, Gastroenterology 2011 141 663 673 10.1053/j.gastro.2011.04.055 21683075
42. Role of TRAIL and the pro-apoptotic Bcl-2 homolog Bim in acetaminophen-induced liver damage. Badmann A, Keough A, Kaufmann T, Bouillet P, Brunner T, Corazza N, Cell Death Dis 2011 2 171 10.1038/cddis.2011.55 21654829
43. Lupulone triggers p38 MAPK-controlled activation of p53 and of the TRAIL receptor apoptotic pathway in human colon cancer-derived metastatic cells. Lamy V, Bousserouel S, Gossé F, Minker C, Lobstein A, Raul F, Oncol Rep 2011 26 109 114 21519792
44. Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents. Sánchez-Pérez T, Ortiz-Ferrán G, Lápez-Rivas A, Cell Death Differ 2010 17 883 894 10.1038/cdd.2009.176 19942932
45. c-Abl stabilizes p73 by a phosphorylation-augmented interaction. Tsai KK, Yuan ZM, Cancer Res 2003 63 3418 3424 12810679 (Pubitemid 36735903)
46. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Jost CA, Marin MC, Kaelin WG Jr, Nature 1997 389 191 194 10.1038/38298 9296498 (Pubitemid 27400602)
47. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D, Cell 1997 90 809 819 10.1016/S0092-8674(00) 80540-1 9288759 (Pubitemid 27357971)
48. Reactive oxygen species up-regulate p53 and Puma; a possible mechanism for apoptosis during combined treatment with TRAIL and wogonin. Lee DH, Rhee JG, Lee YJ, Br J Pharmacol 2009 157 1189 1202 10.1111/j.1476-5381.2009.00245.x 19438509
49. Regulation of p73 by c-Abl through the p38 MAP kinase pathway. Sanchez-Prieto R, Sanchez-Arevalo VJ, Servitja JM, Gutkind JS, Oncogene 2002 21 974 979 10.1038/sj.onc.1205134 11840343 (Pubitemid 34146311)
50. p73 and caspase-cleaved p73 fragments localize to mitochondria and augment TRAIL-induced apoptosis. Sayan AE, Sayan BS, Gogvadze V, Dinsdale D, Nyman U, Hansen TM, Zhivotovsky B, Cohen GM, Knight RA, Melino G, Oncogene 2008 27 4363 4372 10.1038/onc.2008.64 18362891 (Pubitemid 352009995)
51. Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase. Jones EV, Dickman MJ, Whitmarsh AJ, Biochem J 2007 405 617 623 10.1042/BJ20061778 17521288 (Pubitemid 47172060)
52. c-Abl-induced apoptosis, but not cell cycle arrest, requires mitogen-activated protein kinase kinase 6 activation. Cong F, Goff SP, Proc Natl Acad Sci USA 1999 96 13819 13824 10.1073/pnas.96.24.13819 10570156
53. c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy. Galan-Moya EM, Hernandez-Losa J, Aceves Luquero CI, de la Cruz-Morcillo MA, Ramirez-Castillejo C, Callejas-Valera JL, Arriaga A, Aranburo AF, Ramon y Cajal S, Silvio Gutkind J, Sanchez-Prieto R, Int J Cancer 2008 122 289 297 10.1002/ijc.23063 17893873 (Pubitemid 350234714)
54. Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines. Mahalingam D, Keane M, Pirianov G, Mehmet H, Samali A, Szegezdi E, Br J Cancer 2009 100 1415 1424 10.1038/sj.bjc.6605021 19352384
55. Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Jin Z, El-Deiry WS, Mol Cell Biol 2006 26 8136 8148 10.1128/MCB.00257-06 16940186 (Pubitemid 44631011)
56. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D, Ashkenazi A, J Biol Chem 2005 280 40599 40608 10.1074/jbc.M509560200 16227629 (Pubitemid 41780550)
57. MEKK1/MEKK4 are responsible for TRAIL-induced JNK/p38 phosphorylation. Sun BK, Kim JH, Nguyen HN, Oh S, Kim SY, Choi S, Choi HJ, Lee YJ, Song JJ, Oncol Rep 2011 25 537 544 21152872